Ticker brief

KURA KURA ONCOLOGY INC

Consumer, Non-cyclical · Biotechnology

last close
$9.61
1 day
-2.5%
14 days
-9.3%
mkt cap
$985.4M
signals 14d
7
authors 14d
5
crowd 14d
-0.1σ
Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d51%IV/HV 1.00× (as of 2026-09-22)
Skew — 25Δ RR 30d-0.13925Δ call IV − put IV
OI alarmquietlast alarm 2026-06-23 (z=2.0)
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-14 · now +0.25 (−1 bearish … +1 bullish)
Who spoke5
authorgradetrader scoresignalsmean sent
@Quantumup1C+0.102+0.33
@OzmosiHealthC·2+0.13
@PharmdcaC-3.411+0.75
@BiopharmIQB·1+0.10
@TylerHardtA-0.761+0.20
Recent signals7of 7 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-10-14@Quantumup1+0.25Citizens reiterates Market Outperform and a $24 target on KURA.+0.0%
2026-10-13@TylerHardt+0.20Calls an unseen KURA chart a favorite without explaining the setup.-2.2%
2026-10-13@OzmosiHealth+0.15Caspian and Kura outlined the development strategy for diabetes candidate KO-7246.-2.2%
2026-10-07@BiopharmIQ+0.10Summarizes positive midday biotech stock moves alongside company catalysts.-9.9%
2026-10-07@OzmosiHealth+0.10Announces an investor webcast on Caspian's launch and KO-7246 preclinical data.-9.9%
2026-10-06@Pharmdca+0.75Adding to existing positions in INBX, ERAS, KURA, TNGX and BBIO. — Explicitly reports current additions to five biotech positions.-8.7%
2026-10-05@Quantumup1+0.40UBS reiterates Buy on KURA with a $15 target, citing strong launch execution and pipeline potential.-9.5%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.